This HTML5 document contains 40 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dctermshttp://purl.org/dc/terms/
n8http://localhost/temp/predkladatel/
n10http://linked.opendata.cz/resource/domain/vavai/riv/tvurce/
n13http://linked.opendata.cz/ontology/domain/vavai/
n17http://linked.opendata.cz/resource/domain/vavai/zamer/
shttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
n15http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F00216208%3A11120%2F01%3A00003667%21RIV12-MSM-11120___/
n3http://linked.opendata.cz/ontology/domain/vavai/riv/
n2http://linked.opendata.cz/resource/domain/vavai/vysledek/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n4http://linked.opendata.cz/ontology/domain/vavai/riv/klicoveSlovo/
n18http://linked.opendata.cz/ontology/domain/vavai/riv/duvernostUdaju/
xsdhhttp://www.w3.org/2001/XMLSchema#
n9http://linked.opendata.cz/ontology/domain/vavai/riv/jazykVysledku/
n5http://linked.opendata.cz/ontology/domain/vavai/riv/aktivita/
n16http://linked.opendata.cz/ontology/domain/vavai/riv/druhVysledku/
n14http://linked.opendata.cz/ontology/domain/vavai/riv/obor/
n11http://reference.data.gov.uk/id/gregorian-year/

Statements

Subject Item
n2:RIV%2F00216208%3A11120%2F01%3A00003667%21RIV12-MSM-11120___
rdf:type
skos:Concept n13:Vysledek
dcterms:description
In previous papers (1,2) we demonstrated that procaine hydrochloride may increase the therapeutic index of cisplatin by an improvement of its antitumor activity and a reduction of its nephrotoxicity. In the present study we investigated the relationship between the antitumor activity obtained by cisplatin associated with procaine hydrochloride and the relative time of administration of these two agents. When procaine hydrochloride (40 mg/Kg body wt) was administered 30 or 120 minutes before cisplatin (16 mg/kg) diluted in normal saline (i.e. clinical condition) it increased, although not significantly, its percent increase in life span (%ILS) and cure rate (%ILS: +292 and +217 vs +150; cute rate: 46.2% and 42.3% vs 23%, respectively), compared to cisplatin alone treatment. These results became statistically significant when procaine hydrochloride was given either simultaneously with cisplatin ol 30 and 120 minutes thereafter (%ILS: >400 vs +150; cure rate: 65.4% 73.1% and 68% vs 23%, respectively). In previous papers (1,2) we demonstrated that procaine hydrochloride may increase the therapeutic index of cisplatin by an improvement of its antitumor activity and a reduction of its nephrotoxicity. In the present study we investigated the relationship between the antitumor activity obtained by cisplatin associated with procaine hydrochloride and the relative time of administration of these two agents. When procaine hydrochloride (40 mg/Kg body wt) was administered 30 or 120 minutes before cisplatin (16 mg/kg) diluted in normal saline (i.e. clinical condition) it increased, although not significantly, its percent increase in life span (%ILS) and cure rate (%ILS: +292 and +217 vs +150; cute rate: 46.2% and 42.3% vs 23%, respectively), compared to cisplatin alone treatment. These results became statistically significant when procaine hydrochloride was given either simultaneously with cisplatin ol 30 and 120 minutes thereafter (%ILS: >400 vs +150; cure rate: 65.4% 73.1% and 68% vs 23%, respectively).
dcterms:title
Time-dependent influence of procaine hydrochloride on cisplatin antitumor activity in p388 tumor bearing mice Time-dependent influence of procaine hydrochloride on cisplatin antitumor activity in p388 tumor bearing mice
skos:prefLabel
Time-dependent influence of procaine hydrochloride on cisplatin antitumor activity in p388 tumor bearing mice Time-dependent influence of procaine hydrochloride on cisplatin antitumor activity in p388 tumor bearing mice
skos:notation
RIV/00216208:11120/01:00003667!RIV12-MSM-11120___
n3:aktivita
n5:Z
n3:aktivity
Z(AV0Z5039906), Z(MSM 111200001)
n3:cisloPeriodika
1A
n3:dodaniDat
n11:2012
n3:domaciTvurceVysledku
n10:7449186
n3:druhVysledku
n16:J
n3:duvernostUdaju
n18:S
n3:entitaPredkladatele
n15:predkladatel
n3:idSjednocenehoVysledku
698826
n3:idVysledku
RIV/00216208:11120/01:00003667
n3:jazykVysledku
n9:eng
n3:klicovaSlova
cisplatin; procaine; antitumor activity
n3:klicoveSlovo
n4:procaine n4:cisplatin n4:antitumor%20activity
n3:kodStatuVydavatele
GR - Řecká republika
n3:kontrolniKodProRIV
[2E25026399A1]
n3:nazevZdroje
Anticancer Research
n3:obor
n14:EA
n3:pocetDomacichTvurcuVysledku
1
n3:pocetTvurcuVysledku
4
n3:rokUplatneniVysledku
n11:2001
n3:svazekPeriodika
21
n3:tvurceVysledku
Mandys, Václav Viale, M.
n3:wos
000167875900072
n3:zamer
n17:AV0Z5039906 n17:MSM%20111200001
s:issn
0250-7005
s:numberOfPages
3
n8:organizacniJednotka
11120